Physician profile
Daniel Anscher
NPI 1174865745
$1,704.27
in general payments reported to CMS, 2019-2025
9 companies · $1,147 in 2025
The $1,147 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2023: $90.95 · 2024: $15.10 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,097 · Education: $117 · Food and Beverage: $40.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,096.70 |
| Education | $116.65 |
| Food and Beverage | $40.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,096.70 | 2025 | |
| Novocure INC. | $125.00 | 2019 | |
| Celgene Corporation | $124.29 | 2019 | |
| Novo Nordisk INC | $121.60 | 2019 | |
| Seagen INC. | $90.95 | 2023 | |
| Janssen Biotech, INC. | $79.99 | 2019 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Welireg |
| Boston Scientific Corporation | $24.94 | 2025 | Wavewriter Alpha Prime 16 |
| Genentech USA, INC. | $15.10 | 2024 | Columvi, Polivy, Lunsumio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Anscher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.